Kelly Meyers: I’m Starting as Thought Leader Liaison – Oncology at Chimerix, a Jazz Pharmaceuticals Company
Kelly Meyers, Thought Leader Liaison – Oncology at Chimerix, a Jazz Pharmaceuticals Company, shared a post on LinkedIn about her new appointment and the exciting start of her role in this position:
“I’m happy to share that I’m starting a new position as Thought Leader Liaison – Oncology at Chimerix, a Jazz Pharmaceuticals Company!”
About Chimerix, a Jazz Pharmaceuticals Company
Jazz Pharmaceuticals is committed to transforming the lives of patients and their families through innovative science. With a focus on serious diseases where therapeutic options are limited, the company aims to deliver life-changing medicines that help people live more fully and reclaim meaningful moments in their lives.
Jazz has a diverse portfolio that includes leading treatments for sleep disorders, epilepsy, and a growing range of cancer therapies. Their science-driven, patient-focused approach fuels a robust pipeline of novel therapeutics in oncology and neuroscience, advancing research that redefines what’s possible in care.
More Posts Featuring Oncology.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023